Hwang Gyeongjo, Kwon Mincheol, Seo Dongjin, Kim Dae Hoon, Lee Daehwan, Lee Kiwon, Kim Eunyoung, Kang Mingeun, Ryu Jin-Hyeob
Spidercore Inc, 17, Techno 4-ro, Yuseong-gu, Daejeon 34013, South Korea.
BIORCHESTRA Co., Ltd., 17, Techno 4-ro, Yuseong-gu, Daejeon 34013, South Korea.
Mol Ther Nucleic Acids. 2024 Apr 6;35(2):102186. doi: 10.1016/j.omtn.2024.102186. eCollection 2024 Jun 11.
Recent studies have highlighted the effectiveness of using antisense oligonucleotides (ASOs) for cellular RNA regulation, including targets that are considered undruggable; however, manually designing optimal ASO sequences can be labor intensive and time consuming, which potentially limits their broader application. To address this challenge, we introduce a platform, the ASOptimizer, a deep-learning-based framework that efficiently designs ASOs at a low cost. This platform not only selects the most efficient mRNA target sites but also optimizes the chemical modifications for enhanced performance. Indoleamine 2,3-dioxygenase 1 (IDO1) promotes cancer survival by depleting tryptophan and producing kynurenine, leading to immunosuppression through the aryl-hydrocarbon receptor (Ahr) pathway within the tumor microenvironment. We used ASOptimizer to identify ASOs that target IDO1 mRNA as potential cancer therapeutics. Our methodology consists of two stages: sequence engineering and chemical engineering. During the sequence-engineering stage, we optimized and predicted ASO sequences that could target IDO1 mRNA efficiently. In the chemical-engineering stage, we further refined these ASOs to enhance their inhibitory activity while reducing their potential cytotoxicity. In conclusion, our research demonstrates the potential of ASOptimizer for identifying ASOs with improved efficacy and safety.
最近的研究强调了使用反义寡核苷酸(ASO)进行细胞RNA调控的有效性,包括针对那些被认为难以成药的靶点;然而,手动设计最佳的ASO序列可能既费力又耗时,这可能会限制它们的更广泛应用。为了应对这一挑战,我们引入了一个平台——ASOptimizer,这是一个基于深度学习的框架,能够以低成本高效地设计ASO。该平台不仅能选择最有效的mRNA靶位点,还能优化化学修饰以提高性能。吲哚胺2,3-双加氧酶1(IDO1)通过消耗色氨酸和产生犬尿氨酸来促进癌症存活,从而通过肿瘤微环境中的芳烃受体(Ahr)途径导致免疫抑制。我们使用ASOptimizer来鉴定靶向IDO1 mRNA的ASO作为潜在的癌症治疗药物。我们的方法包括两个阶段:序列工程和化学工程。在序列工程阶段,我们优化并预测了能够有效靶向IDO1 mRNA的ASO序列。在化学工程阶段,我们进一步优化这些ASO,以增强其抑制活性,同时降低其潜在的细胞毒性。总之,我们的研究证明了ASOptimizer在鉴定具有更高疗效和安全性的ASO方面的潜力。